Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Cancer Cell-Specific Hyperthermic Chemotherapy Treatment for Surgery-Resistant Abdominal Cancers (Ref # WFU 07-07)
Wake Forest Innovations USA flag USA
Abstract ID:
This treatment uses nanoparticle technology to deliver hyperthermic chemotherapy to patients with metastatic abdominal cancer. This enables intraperitoneal chemotherapy to be delivered using lower doses with higher efficacy, thus limiting toxicity....
Contact Charlie Shaw
Participants
You
Email me a copy of this message
Value Proposition

Cancers of the abdomen, such as stomach, colorectal, or ovarian cancer, are difficult to treat effectively due to their tendency to metastasize. The current state-of-the-art treatment, intraperitoneal hyperthermic chemotherapy (IPHC), is effective against tumor cells but also causes undesirable side effects in healthy cells. By incorporating nanoparticle-based compositions into the treatment plan, researchers maximize IPHC efficacy while minimizing side effects due to drug interaction with healthy cells.

Invention Summary

Researchers at Wake Forest University have developed novel nanoparticle-based compositions that can be used to maximize the effectiveness of IPHC while reducing the toxicity of the chemotherapeutic agent to healthy cells. To maximize effectiveness, anti-cancer drugs are heated and then circulated through the peritoneum. Methods of using this composition have been shown experimentally in vitro to reduce the therapy time by over 200 fold (from 2 hours to a mere 30 seconds).

Competitive Benefits

• Reduction in time of drug perfusion from hours to seconds

• Requires no attachment of cancer drugs to the nanoparticle

• Potential reduction in patient side effects

• Reduction in the amount of anti-cancer drug needed, drastically reducing cost

Application Fields

• Novel nanoparticle-based compositions promise to maximize the effectiveness of IPHC

• This technology could be incorporated into a wide range of other hyperthermic-based chemotherapeutics

Stage of Development

• Proof-of-principle studies in vitro demonstrated the ability of nanoparticle-based compositions to reduce therapy time by over 200 fold.

• Preclinical – animal model completed

Background

Intraperitoneal hyperthermic chemotherapy (IPHC) is a promising therapy for peritoneal dissemination of colorectal and appendiceal cancers. IPHC involves a multi-hour circulation of heated anti-cancer drugs (such as oxaliplatin or mitomycin C) in the peritoneum. Hyperthermia increases cellular metabolism and membrane permeability, resulting in enhanced drug uptake by cells. Although IPHC has significantly improved patient outcomes, the procedure is hampered by the time that the patient must be anesthetized (hours) and the amount of drug perfusate necessary (liters).

Publications

• Levi-Polyachenko, et al . Rapid Photothermal Intracellular Drug Delivery Using Multiwalled Carbon Nanotubes. Molecular Pharmaceutics 2009 Jul-Aug;6(4):1092-9.

• “Nanotubes for rapid photothermal intracellular drug delivery.” SciBX . July 9, 2009.

Inventors

• Nicole Hope Levi, PhD

Plastic and Reconstructive Surgery

• John H. Stewart, IV, MD

Surgical Oncology

• David L. Carroll, PhD

Physics

Key Words

• Hyperthermic chemotherapy treatment

• Intraperitoneal chemotherapy

• Nanoparticle technology

• Abdominal cancer

Contact

Charlie Shaw, PhD

Wake Forest Innovations

Commercialization Associate

Tel: +1.336.716.3729

Email: chshaw@wakehealth.edu
GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
Exclusive Licensing Arrangement
Possibility of a parallel Sponsored Research Agreement
FEATURED
Last Updated Feb 2014
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL
CORPORATION